Aldeyra Therapeutics Inc News - ALDX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

Form 8-K - Current report

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

PDUFA Date is April 2, 2025 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA...

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

👍️0

Investor2014 4 weeks ago

The case has gone nowhere since Jul 24, 2024 "Motion Hearing AND Order on Motion to Dismiss" docket 42 - I believe dismissed, but haven't access to read the docket.

👍️0

jgrabar 3 months ago

Current Aldeyra shareholders who have continuously held Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/ to learn more. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

👍️0

TechandBio 3 months ago

Another big winner for me this year ICCM is next!

$ALDX

👍️0

Investor2014 4 months ago

Sold half at around $5’ish for about 50% profit looking to buy back lower awaiting NDA filing and like decision dates for Reproxalap.

👍️0

peterus 4 months ago

what your thoughts here for the future?

👍️0

peterus 4 months ago

hi bro you know a good discord or web for parma and bio´s

Investor2014 4 months ago

No one happy here?

👍️0

Investor2014 4 months ago

Will the dry eye confirmatory P3 trial prove successful this morning? Hard to call, but leaning towards yes.

👍️0

Monksdream 8 months ago

ALDX under $4

👍️0

jgrabar 8 months ago

NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.

👍️0

InvestorPhilia4 9 months ago

Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?

👍️0

Monksdream 12 months ago

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

InvestorPhilia4 1 year ago

I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.

👍️0

Invest-in-America 1 year ago

ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)

👍️0

green maschine 1 year ago

Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.

👍️0

Invest-in-America 1 year ago

Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

👍️0

green maschine 1 year ago

Yep. I snatched up some of this pre-market.

👍️0

Invest-in-America 1 year ago

ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!

👍️0

Investor2014 1 year ago

I bought to average down today, it seems a sensible move.

👍️0

InvestorPhilia4 1 year ago

With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.

👍️0

Investor2014 1 year ago

Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.

👍️0

InvestorPhilia4 1 year ago

Ouch

👍️0

Investor2014 1 year ago

A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…

👍️0

InvestorPhilia4 2 years ago

I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.

👍️0

Investor2014 2 years ago

Yet another great day for aldeyra.

No one invested here?

👍️0

Investor2014 2 years ago

Another great day for Aldeyra. In due course probably pay handsomely.

👍️0

Investor2014 3 years ago

Good day for Aldeyra!

👍️0

Investor2014 3 years ago

That’s biotech.

👍️0

TheFinalCD 3 years ago

what I meant was the time line

mid 2022

👍️0

Investor2014 3 years ago

Agree and believe that is what I just said.

👍️0

TheFinalCD 3 years ago

yeah but heres the kicker

ALDX
Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022

👍️0

Investor2014 3 years ago

So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

Could be fine not least given that secondary p-value.

Still hope!

👍️0

TheFinalCD 3 years ago

ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html

👍️0

Investor2014 3 years ago

Yeah not good.

👍️0

TheFinalCD 3 years ago

NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
T1

👍️0

Investor2014 3 years ago

Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

👍️0

Rayn_Makr 4 years ago

ADX-1612 and ADX-1615, Chaperome Inhibitors

Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor

👍️0

Investor2014 4 years ago

I agree, ALDX has great potential.

👍️0

Rayn_Makr 4 years ago

RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!

👍️0

Rayn_Makr 4 years ago

Perceptive Advisors SEC form 4
3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?

👍️0

Investor2014 4 years ago

It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.

👍️0

make it happen 4 years ago

I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.

👍️0

Investor2014 4 years ago

Bought in again @$12.89.

👍️0

make it happen 4 years ago

Huge $125,000,000 offering & can add another $18,750,000 million

👍️0

make it happen 4 years ago

Most def

👍️0

Investor2014 4 years ago

Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

Plenty time to buy back in cheaper, which should be a nice long term hold.

👍️0

ClayTrader 4 years ago

* * $ALDX Video Chart 04-27-2021 * *

Link to Video - click here to watch the technical chart video

👍️0

make it happen 4 years ago

Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Aldeyra Therapeutics Inc (ALDX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALDX News

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Form 8-K - Current report

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ALDX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Aldeyra Therapeutics Inc (ALDX) News

Aldeyra Therapeutics Inc (ALDX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALDX News

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Form 8-K - Current report

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ALDX Discussion

Your Recent History

Company

Business

Popular

Get The App